EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab

Dear Sirs,

A 56 year old man was diagnosed with B-chronic lymphocytic leukemia (B-CLL) in another hospital (RAI 4, BINET C, IGHV mutated; FISH: 59% of cells trisomy 12). Treatment was started with fludarabine, cyclophosphamide and alemtuzumab. The patient received pneumocystis jiroveci pneumonia prophylaxis and herpes prophylaxis with sulphamethoxazole–trimethoprim and valacyclovir. Evaluation after two cycles showed evidence of response. Screening for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) antibodies using ELISA was repeatedly negative. After 2 months the patient developed memory loss and a sensory aphasia, and treatment including alemtuzumab was discontinued. A cerebral MRI scan revealed several lesions with some irregular and faint ring enhancement in the occipital and frontal lobe of the left hemisphere and the frontal lobe of the right hemisphere, with high signal intensity on T2 weighted images (Fig. 1). Treatment with amoxicillin and cefotaxime was started and the patient was referred to our hospital. Cerebrospinal fluid (CSF) showed 10 leucocytes (71% lymphocytes) with an elevated total protein (1,08 g/l), normal glucose and a monoclonal B-cell population consistent with the B-CLL (CD5, CD19 and CD23 positive). All CSF cultures for micro-organisms were negative. Two days after the last negative IgG and IgM screening for EBV, PCR for EBV in serum and CSF showed high numbers of viral copies, respectively, 5,01E5 and 1,31E4. A biopsy of the left parieto–occipital lesion revealed a diffuse large B-cell lymphoma (DLBCL), positive for CD79a and CD23 and nuclear Pax-5. MIB-1 labeling was positive in 85% of the tumor cells. The nuclear EBV-encoded RNA stain (EBER) was strongly positive, fitting in with the development of an EBV-associated lymphoma. Despite high dose dexamethasone the patient deteriorated rapidly and he died 15 days after the initial MRI cerebrum. Autopsy was not performed.

Fig. 1

Cerebral MRI Axial MRI images a–c showing lesions in the central and occipital regions of the left hemisphere and frontal region of the right hemisphere with low signal intensity on T1-weighted sequences (a), faint ring enhancement on T1-weighted sequences after gadolinium (b) and high signal intensity with subtle low signal intensity parts on T2 weighted sequences (c). The low signal intensity parts on T2 weighted sequences suggests a lymphoma, but the faint ring enhancement is not typical for this diagnosis

Symptomatic CNS involvement in patients with B-CLL is an uncommon complication and generally limited to the meninges. Intracerebral localisations are exceedingly rare [4]. Although development of an aggressive large-cell lymphoma in patients with an underlying CLL occurs in 1–10% of patients, only six case reports on malignant transformation of CLL (or Richter’s transformation) involving the brain parenchyma have been published [2].

Alemtuzumab (Campath-1H) is an anti-CD52 humanized monoclonal antibody [6]. It is indicated for poor prognosis CLL and the drug is being investigated in combination therapies for a variety of hematological malignancies and in multiple sclerosis. Because of its effects on B and T lymphocytes with prolonged T-cell deficiency, the drug is highly immunosuppressive. Indeed, alemtuzumab is associated with a variety of opportunistic infections, especially CMV reactivation, herpes simplex virus, and aspergillus infections [6]. In addition, in alemtuzumab treated patients, EBV reactivation has been described and several cases of EBV associated systemic lymphoma have been reported [5, 7].

Our patient developed a cerebral EBV-positive immunodeficiency lymphoma during alemtuzumab treatment. The positive CD23 staining makes a transformation from the known B-CLL a theoretical possibility, but otherwise no clonal relationship between the CLL and NHL were observed. Both in CSF and serum high copy numbers of EBV were demonstrated. Moreover, the EBER staining of the biopsy specimen was positive, identifying the relation with EBV. Of note, in occasional cases of malignant transformation in CLL, EBV has been identified in the higher-grade neoplasm [3]. A retrospective study showed 16% of 25 patients with malignant transformation of CLL to be EBV-positive, indicating a role for EBV in malignant transformation in leukemia [1]. In our case, PCR EBV and CMV monitoring was not performed during treatment with alemtuzumab, and the ELISA assay for anti-EBV antibodies remained negative. Only when the patient developed severe neurological symptoms the EBV PCR was done which revealed both in serum and CSF the EBV reactivation. PCR techniques detecting EBV have a high sensitivity compared to the detection of antibodies with ELISA and are not influenced by an immunocompromised state.

Because of the increasing use of alemtuzumab and the profound and lasting immunosuppression this drug induces, neurologists should be aware of opportunistic infections including EBV. Regular monitoring of EBV and CMV using PCR is indicated in patients treated with alemtuzumab. If alemtuzumab treated patients develop neurological signs and symptoms, opportunistic infections and EBV induced lymphoma must be considered.